Log in to save to my catalogue

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients...

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1a80d93b46254b83bfdf5d4c0de1a368

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

About this item

Full title

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Publisher

London: BioMed Central

Journal title

Journal of experimental & clinical cancer research, 2022-06, Vol.41 (1), p.189-19, Article 189

Language

English

Formats

Publication information

Publisher

London: BioMed Central

More information

Scope and Contents

Contents

Background
Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumor activity in preclinical models. This study was designed to determine the recommended phase 2 dose (RP2D), characterize PK/PD,...

Alternative Titles

Full title

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_1a80d93b46254b83bfdf5d4c0de1a368

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1a80d93b46254b83bfdf5d4c0de1a368

Other Identifiers

ISSN

1756-9966,0392-9078

E-ISSN

1756-9966

DOI

10.1186/s13046-022-02383-5

How to access this item